CD40LG and inflammatory bowel disease: Generalised disruption of the CD40–CD154 pathway was attempted in clinical trials of individuals with lupus nephritis and inflammatory bowel disease (CD40-driven diseases) using neutralising monoclonal antibody (mAb) against CD154 [10].